Replimune said on May 29, 2026 that it reached an agreement with the FDA to resubmit its application for RP1 (vusolimogene oderparepvec) for advanced melanoma in combination with Bristol Myers Squibb's Opdivo. The therapy had previously received a complete response letter over concerns that supporting evidence relied on a single-arm study without a control group.
The new path follows intense debate over how the FDA should evaluate therapies for patients with advanced, treatment-resistant cancer. Patient communities, clinicians, and policymakers have argued over urgency for seriously ill patients versus the need for reliable evidence that a treatment helps.
What advocates should watch
Watch whether the FDA applies consistent standards to single-arm oncology data, how it communicates uncertainty to patients, and whether the resubmission includes stronger evidence or a clearer post-approval data collection plan. Oncology advocates should document what patients are told about benefits and limits if the product moves toward approval.
Related: Reuters report, Replimune FDA response release.
Access while review is pending
A resubmission agreement does not guarantee approval. Patients awaiting RP1 combinations should ask oncology teams about clinical trials, expanded access, and coverage for alternative immunotherapies already on formulary.
Document medical necessity and prior therapies tried when requesting formulary exceptions or expedited prior authorization for substitute regimens.
Guides on patientadvocates.io
For step-by-step help, start with our Goals of care guide or browse related topics including Palliative care, Informed consent.